{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:58:21Z","timestamp":1793314701667,"version":"4.5.0"},"reference-count":115,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-cell lymphomas with remarkable genetic heterogeneity and myriad clinical presentations. Multiplatform genomic analyses of DLBCL have identified oncogenic drivers within genetic subtypes that allow for pathologic subclassification of tumors into discrete entities with shared immunophenotypic, genetic, and clinical features. Robust classification of lymphoid tumors establishes a foundation for precision medicine and enables the identification of novel therapeutic vulnerabilities within biologically homogeneous entities. Most cases of DLBCL involving the central nervous system (CNS), vitreous, and testis exhibit immunophenotypic features suggesting an activated B-cell (ABC) origin. Shared molecular features include frequent comutations of MYD88 (L265P) and CD79B and frequent genetic alterations promoting immune evasion, which are hallmarks of the MCD\/C5\/MYD88 genetic subtype of DLBCL. Clinically, these lymphomas primarily arise within anatomic sanctuary sites and have a predilection for remaining confined to extranodal sites and strong CNS tropism. Given the shared clinical and molecular features, the umbrella term primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) was proposed. Other extranodal DLBCL involving the breast, adrenal glands, and skin are often ABC DLBCL but are more heterogeneous in their genomic profile and involve anatomic sites that are not considered immune privileged. In this review, we describe the overlapping clinical, pathologic, and molecular features of IP-LBCL and highlight important considerations for diagnosis, staging, and treatment. We also discuss potential therapeutic vulnerabilities of IP-LBCL including sensitivity to inhibitors of Bruton tyrosine kinase, immunomodulatory agents, and immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020911","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:09:44Z","timestamp":1713449384000},"page":"2593-2603","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Primary large B-cell lymphomas of immune-privileged sites"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"first","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-2485","authenticated-orcid":false,"given":"James D.","family":"Phelan","sequence":"additional","affiliation":[{"name":"1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2024121916205388600_bib1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024121916205388600_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"2024121916205388600_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"20","key":"2024121916205388600_bib4","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2024121916205388600_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024121916205388600_bib6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2024121916205388600_bib7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2024121916205388600_bib8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1182\/blood.2021011366","article-title":"Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1\/PD-L1\/PD-L2 alterations","volume":"138","author":"Minderman","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024121916205388600_bib9","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"2024121916205388600_bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2019001185","article-title":"High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites","volume":"134","author":"Elfrink","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2024121916205388600_bib11","first-page":"1598","article-title":"The molecular hallmarks of primary and secondary vitreoretinal lymphoma","volume":"6","author":"Bonzheim","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2024121916205388600_bib12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.2020008520","article-title":"EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity","volume":"137","author":"Gandhi","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2024121916205388600_bib13","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/bloodadvances.2022009521","article-title":"Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS","volume":"7","author":"Guney","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2024121916205388600_bib14","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1158\/0008-5472.CAN-22-3814","article-title":"Large B-cell lymphomas of immune-privileged sites relapse via parallel clonal evolution from a common progenitor B cell","volume":"83","author":"Los-de Vries","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"2024121916205388600_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T","article-title":"Testicular lymphoma is associated with a high incidence of extranodal recurrence","volume":"88","author":"Fonseca","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"2024121916205388600_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/cns.15.34","article-title":"Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy","volume":"4","author":"Ambady","year":"2015","journal-title":"CNS Oncol"},{"key":"2024121916205388600_bib17","first-page":"1","article-title":"Immunologically privileged sites","volume":"25","author":"Barker","year":"1977","journal-title":"Adv Immunol"},{"issue":"9","key":"2024121916205388600_bib18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024121916205388600_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"suppl 5","key":"2024121916205388600_bib20","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"9","key":"2024121916205388600_bib21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"2024121916205388600_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024121916205388600_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2024121916205388600_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"2024121916205388600_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.59.5.762","article-title":"Is a \"vanishing tumor\" always a lymphoma?","volume":"59","author":"Bromberg","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"2024121916205388600_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"2024121916205388600_bib27","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024121916205388600_bib28","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024121916205388600_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","article-title":"Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report","volume":"18","author":"Grimm","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"2024121916205388600_bib30","doi-asserted-by":"crossref","first-page":"e52385","DOI":"10.1371\/journal.pone.0052385","article-title":"Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis","volume":"8","author":"Fisson","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2024121916205388600_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","article-title":"High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates","volume":"126","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2024121916205388600_bib32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.15005","article-title":"Clinical features and outcomes of secondary intraocular lymphoma","volume":"183","author":"Karakawa","year":"2018","journal-title":"Br J Haematol"},{"issue":"31","key":"2024121916205388600_bib33","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2009.22.5896","article-title":"Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab","volume":"27","author":"Gundrum","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024121916205388600_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2007.08.005","article-title":"Primary testicular lymphoma","volume":"65","author":"Vitolo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2024121916205388600_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024121916205388600_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/leu.2015.237","article-title":"Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium","volume":"30","author":"Deng","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2024121916205388600_bib37","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/bloodadvances.2023011251","article-title":"IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma","volume":"8","author":"Conconi","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2024121916205388600_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.14392","article-title":"Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era","volume":"176","author":"Kridel","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2024121916205388600_bib39","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood.2020006338","article-title":"Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma","volume":"137","author":"Twa","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2024121916205388600_bib40","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024121916205388600_bib41","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood-2017-04-737445","article-title":"Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks","volume":"132","author":"Ponzoni","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2024121916205388600_bib42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/PAS.0000000000001978","article-title":"Intravascular large B-cell lymphoma genomic profile is characterized by alterations in genes regulating NF-kappaB and immune checkpoints","volume":"47","author":"Gonzalez-Farre","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2024121916205388600_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(09)70140-8","article-title":"Presentation and management of intravascular large B-cell lymphoma","volume":"10","author":"Shimada","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024121916205388600_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/12034754221130257","article-title":"Recommendations for an approach to random skin biopsy in the diagnosis of intravascular B-cell lymphoma","volume":"27","author":"MacGillivary","year":"2023","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"2","key":"2024121916205388600_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","article-title":"Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'","volume":"127","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"2024121916205388600_bib46","first-page":"826","article-title":"An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome","volume":"111","author":"Murase","year":"2000","journal-title":"Br J Haematol"},{"issue":"11","key":"2024121916205388600_bib47","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.2020007245","article-title":"Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma","volume":"137","author":"Shimada","year":"2021","journal-title":"Blood"},{"issue":"6769","key":"2024121916205388600_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"12","key":"2024121916205388600_bib49","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"17","key":"2024121916205388600_bib50","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A\u00a0gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"2024121916205388600_bib51","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024121916205388600_bib52","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024121916205388600_bib53","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024121916205388600_bib54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.17246","article-title":"Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance","volume":"192","author":"Ahmed","year":"2021","journal-title":"Br J Haematol"},{"issue":"7332","key":"2024121916205388600_bib55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"7277","key":"2024121916205388600_bib56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"7360","key":"2024121916205388600_bib57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"9","key":"2024121916205388600_bib58","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"issue":"10","key":"2024121916205388600_bib59","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2024121916205388600_bib60","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2024121916205388600_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2024121916205388600_bib62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jnen\/nlz125","article-title":"Molecular subtypes and genomic profile of primary central nervous system lymphoma","volume":"79","author":"Bodor","year":"2020","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"19","key":"2024121916205388600_bib63","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024121916205388600_bib64","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"2024121916205388600_bib65","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3109\/10428194.2014.979413","article-title":"Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations","volume":"56","author":"Yamada","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2024121916205388600_bib66","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2024121916205388600_bib67","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2024121916205388600_bib68","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","article-title":"MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas","volume":"3","author":"Nayyar","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"2024121916205388600_bib69","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2024121916205388600_bib70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2024121916205388600_bib71","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2024121916205388600_bib72","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2024121916205388600_bib73","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"2024121916205388600_bib74","unstructured":"A\u00a0study of nivolumab in relapsed\/refractory primary central nervous system lymphoma (PCNSL) and relapsed\/refractory primary testicular lymphoma (PTL). 2021. ClinicalTrials.gov identifier: NCT02857426. Updated 24 November. Accessed 19 March 2024. https:\/\/clinicaltrials.gov\/study\/NCT02857426."},{"issue":"suppl 1","key":"2024121916205388600_bib75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-141773","article-title":"First results of the Acs\u00e9 Pembrolizumab phase II in the primary CNS lymphoma (PCNSL) cohort [abstract]","volume":"136","author":"Hoang-Xuan","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2024121916205388600_bib76","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"2024121916205388600_bib77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2023.12.019","article-title":"Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy","volume":"42","author":"Phelan","year":"2024","journal-title":"Cancer Cell"},{"issue":"7718","key":"2024121916205388600_bib78","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A\u00a0multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"issue":"11","key":"2024121916205388600_bib79","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-kappaB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024121916205388600_bib80","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"2024121916205388600_bib81","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.clml.2022.06.002","article-title":"SOHO state of the art updates and next questions: prophylaxis and management of secondary CNS lymphoma","volume":"22","author":"Simard","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"2024121916205388600_bib82","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"2024121916205388600_bib83","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study","volume":"40","author":"Houillier","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024121916205388600_bib84","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024121916205388600_bib85","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6","key":"2024121916205388600_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group","volume":"38","author":"Colombat","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2024121916205388600_bib87","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024121916205388600_bib88","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.26919","article-title":"Older patients with primary central nervous system lymphoma: survival and prognostication across 20 U.S. cancer centers","volume":"98","author":"David","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2024121916205388600_bib89","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2024121916205388600_bib90","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2024121916205388600_bib91","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"issue":"10","key":"2024121916205388600_bib92","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1080\/10428194.2019.1594219","article-title":"Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma","volume":"60","author":"Biccler","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2024121916205388600_bib93","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"issue":"17","key":"2024121916205388600_bib94","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024121916205388600_bib95","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","article-title":"Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study","volume":"133","author":"Riemens","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2024121916205388600_bib96","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.83.4.448","article-title":"Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma","volume":"83","author":"de Smet","year":"1999","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2024121916205388600_bib97","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.exer.2005.09.018","article-title":"The pharmacokinetics of rituximab following an intravitreal injection","volume":"82","author":"Kim","year":"2006","journal-title":"Exp Eye Res"},{"issue":"20","key":"2024121916205388600_bib98","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024121916205388600_bib99","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3816\/CLM.2009.n.075","article-title":"Rituximab and dose-dense chemotherapy in primary testicular lymphoma","volume":"9","author":"Aviles","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"2024121916205388600_bib100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Shimada","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024121916205388600_bib101","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"2024121916205388600_bib102","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"2024121916205388600_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"2024121916205388600_bib104","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","article-title":"Overcoming acquired epigenetic resistance to BTK inhibitors","volume":"2","author":"Shaffer","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2024121916205388600_bib105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024121916205388600_bib106","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2024121916205388600_bib107","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024121916205388600_bib108","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/187152011795347487","article-title":"Lenalidomide - current understanding of mechanistic properties","volume":"11","author":"Tageja","year":"2011","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"4","key":"2024121916205388600_bib109","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"issue":"13","key":"2024121916205388600_bib110","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2024121916205388600_bib111","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"21","key":"2024121916205388600_bib112","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2024121916205388600_bib113","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121916205388600_bib114","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2022-165256","article-title":"A\u00a0pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed\/refractory primary and secondary central nervous system lymphoma (CNSL) [abstract]","volume":"140","author":"Jacobson","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024121916205388600_bib115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in PCNSL and SCNSL: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2593\/2347027\/blood_bld-2023-020911-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2593\/2347027\/blood_bld-2023-020911-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:32:03Z","timestamp":1734607923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/25\/2593\/515774\/Primary-large-B-cell-lymphomas-of-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":115,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020911","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}